Details:

Alternative Title:
Infect Drug Resist
Personal Author:
Berkow, Elizabeth L ; Lockhart, Shawn R
Berkow, Elizabeth L ; Lockhart, Shawn R Less -
Description:
Candida albicans and the emerging non-albicans Candida spp. have significant clinical relevance among many patient populations. Current treatment guidelines include fluconazole as a primary therapeutic option for the treatment of these infections, but it is only fungistatic against Candida spp. and both inherent and acquired resistance to fluconazole have been reported. Such mechanisms of resistance include increased drug efflux, alteration or increase in the drug target, and development of compensatory pathways for producing the target sterol, ergosterol. While many mechanisms of resistance observed in C. albicans are also found in the non-albicans species, there are also important and unexpected differences between species. Furthermore, mechanisms of fluconazole resistance in emerging Candida spp., including the global health threat Candida auris, are largely unknown. In order to preserve the utility of one of our fundamental antifungal drugs, fluconazole, it is essential that we fully appreciate the manner by which Candida spp. manifest resistance to it.
Subject:
[+]
Candida
Drug Efflux
ERG11
Ergosterol
Fluconazole Resistance
Review

Source:
Infect Drug Resist. 2017; 10:237-245.
Pubmed ID:
28814889
Pubmed Central ID:
PMC5546770
Document Type:
Journal Article
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:f98321b7bdcdbd0db6eb4f7a83ef8540b7b30e9fcf83e244e30174b2adc13c86
File Type:

Supporting Files

• idr-10-237.nxml

  bin

More +